Stock ANR ANATARA LIFESCIENCES LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Anatara Lifesciences Ltd

Equities

ANR

AU000000ANR0

Market Closed - Australian S.E.
Other stock markets
 12:31:52 2024-04-18 am EDT 		5-day change 1st Jan Change
0.042 AUD 0.00% Intraday chart for Anatara Lifesciences Ltd +2.44% +90.91%
Apr. 09 Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial MT
Feb. 28 Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial
MT
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer
MT
Anatara Lifesciences Limited Webinar on the Company's Stage 1 Irritable Bowel Syndrome
AW
Anatara Lifesciences Limited (ASX:ANR) Webinar on the Company's Stage 1 Irritable Bowel Syndrome
AQ
Anatara Lifesciences Ltd Announces Board Changes
CI
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial
MT
Anatara Lifesciences Finalizes Patients for Irritable Bowel Syndrome Clinical Trial Stage One
MT
Anatara Lifesciences Ltd Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3%
MT
Anatara Lifesciences Ltd Announces Registered Office Change
CI
Anatara Lifesciences Provides Update on the Gastrointestinal Reprogramming(Garp) Trial for IBS
CI
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2022
CI
Anatara Lifesciences Ltd Announces board Changes
CI
Anatara Lifesciences Raising Funds for Patient Trial, Future Project Acquisitions
MT
Anatara Lifesciences Receives More than $310,000 R&D Tax Rebate
MT
CSIRO Halts Psychological Functioning Trial for Dietary Supplement
MT
Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial
CI
Anatara Lifesciences Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
Anatara Lifesciences Modifies Protocol for Upccoming Gastrointestinal Disease Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANR Stock
  4. News Anatara Lifesciences Ltd